Form 4 Edwards Lifesciences For: Feb 01 Filed by: Ullem Scott B.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Edwards Lifesciences (EW) shares rally on Evoque FDA approval
February 2, 2024 11:26 AM ESTEdwards Lifesciences (NYSE: EW) shares are rallying Friday after the companys EVOQUE tricuspid valve replacement system was approved by the U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
EW shares are up more than 7% at $84.50 per share at the... More
